Please type a plus sign (+) inside this box → +

PK3065US3

PTO/SB/05 (03-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Attorney Docket No.

First Inventor

PATENT APPLICATION **TRANSMITTAL**

Title

DOWER Peptides and Compounds that Bind to a Thrombopoietin.

(Only for new	v nonprovisional applications under 37	CFR 1.53(b)) Express	Mail Label No.		EV02	2025865US	_>2		
	APPLICATION ELEME	NTS				Commissioner for Patents	107		
See MPEP	chapter 600 concerning utility pater	nt application contents.	AL			n, D.C. 20231	Ü		
1. V	ee Transmittal Form (e.g., PTO Submit an original, and a duplicate fo	r fee processing)	(Computer Progra	ım <i>(Appe</i>	•			
	opplicant claims small entity stati see 37 CFR 1.27.	us.		ide and/or Amino able, all necessary)		equence Submission			
	pecification [Total Pages 95] referred arrangement set forth below) Descriptive title of the invention		a. [<u> </u>		e Form (CRF)			
-			b. Specification Sequence Listing on:						
		Cross Reference to Related Applications		i. CD-R	OM or C	D-R (2 copies); or			
	 Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, 			ii. 🚺 paper					
	or a computer program listing appendix Background of the Invention		с. [✓ Statement	s verifyin	ng identity of above co	pies		
	- Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure			ACCOMPANYING APPLICATION PARTS					
				Assignment Papers (cover sheet & document(s))					
-				10. 37 CFR 3.73(b) Statement (when there is an assignee) Power of Attorney					
				11. English Translation Document (if applicable)					
4. 🗸 🏻 🗅	Orawing(s) (35 U.S.C. 113) [To	otal Sheets 15]		nformation Disclo		9 Copies of ID Citations	os		
5. Oath or l	Declaration [To	otal Pages 3]	13 🗸 P	reliminary Amen	dment				
а.	Newly executed (original	al or copy)	14. 7 8	teturn Receipt Po	ostcard (MPEP 503)			
ь. [Copy from a prior applic) [Should be specifical certified Copy of					
J 0. [(for continuation/divisional v			f foreign priority is a		Jocument(s)			
	i. DELETION OF I		116 1 1 4			nder 35 U.S.C. 122	2/25		
	Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.								
	1 63(d)(2) and 1.33(b).								
	Application Data Sheet. See 37			Other:					
	ONTINUING APPLICATION, ct cation Data Sheet under 37 CFR 1.7		supply the requisite	e information below	and in a	preliminary amendment,			
Continuation Divisional Continuation-in-part (CIP) of prior application No.: 09/549,090									
Prior application information Examiner <u>Davenport, A.M.</u> For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied									
under Box 5	5b, is considered a part of the dis he incorporation can only be relied	clósure of the accompai d upon when a portion h	nying continuations been inadverte	n or divisional apently omitted from	pplication	and is hereby incorpo	rated by		
		19. CORRESPO	NDENCE ADI	DRESS					
X Custo	omer Number or Bar Code Label	(Insert Customering on A	eci le con ebe	or [Corre	spondence address belov	N		
	1-1	73	347						
Name		PATENT TRA	DEMARK OFFICE						
Addrons									
Address									
City		State		Zip	Code				
Country		Telephone			Fax				
Name	(Print/Type) Virginia C. Bennett		Regist	ration No. (Attorne	y/Agent)	37,092	1		
Signa		. o+A			Date	27 Feb. 02	7		
	1 100-11	A U/A/1				DE / 100. U.S.			

Burden Hour Statement: This foom is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, IOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Box DC 20231.

Express Mail Label No. EV022025865US

PTO/SB/17 (11-01)

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to espond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002			Complete if Known						
for EV 2002		Appli	cation	Numbe	To be as	signed			
101 F 1 2002		Filing	Date		Concurr	ently here	with		
Patent fees are subject to annual revision.		First	Named	Inven	tor DOWER	₹			
Applicant claims small entity status. See 37 CFR 1.	27	Exam	niner N	ame					
		Grou	p Art U	Init					
TOTAL AMOUNT OF PAYMENT \$74	0.00	Attori	ney Do	cket N	o. PU3065	US3			
METHOD OF PAYMENT (check all that apply)	1			FEE	CALCULAT	TION (con	itinued)		
Check Credit card Mone Other None	3. A[DITIC	NAL F	EES			,		
Deposit Account:	Large F		Small Fee	Entity Fee	5 D		_	ree Deid	
Deposit	Code	(\$)	Code	(\$)	רee ב Surcharge - late fi	escription		Fee Paid	
Account Number 07-1392	105 127	130 50	205 227		Surcharge - late in Surcharge - late p	•			
Deposit Account GlaxoSmithKline				5	sheet				
Name	139	130	139		Non - English spe		to roovamination		
The Commissioner is authorized to: (check all that apply)		2,520	l		For filing a reques		R prior to Examiner		
Charge fee(s) indicated below Credit any overpayments	112	920*		á	action				
Charge any additional fee(s) during the pendency of this application	113	1,840*	1131		Requesting public action	cation of SIF	arter Examiner		
Charge fee(s) indicated below, except for the filing fee to the above identified deposit account	115	110	215	55 l	Extension for repl	ly within firs	t month		
FEE CALCULATION	116	400	216	200	Extension for repl	ly within sec	cond month		
1. BASIC FILING FEE	117	920	217		Extension for repl	-			
Large Entity Small Entity	118	·	218		Extension for repl	•			
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	128		228		Extension for repl	iy witnin tifti	i month		
101 740 201 370 Utility filing fee 740.00	119	320	219		Notice of Appeal Filing a brief in su	innort of an	anneal		
106 330 206 165 Design filing fee	120 121	320 280	220		Request for oral l		иррси		
107 510 207 255 Plant filing fee	138		1		Petition to institut		se proceeding		
108 740 208 370 Reissue filing fee	140		240	•	Petition to revive				
114 160 214 80 Provisional filing fee		1,280	241	640	Petition to revive	- unintentio	nal		
		1,280	242	640	Utility issue fee (d	or reissue)			
2. EXTRA CLAIM FEES FOR UTILITY AND Fee from	143	460	243	230	Design issue fee				
Extra Claims below Fee Pale	144	620	244	310	Plant issue fee				
Total Claims 18 -20^* = 0 X 18.00 = 0.00 independent 2 - 3** = 0 X 84.00 = 0.00	122	130	122		Petitions to the C				
Claims Multiple Dependent	123	50	123		Processing fee u				
Large Entity Small Entity	126	180	126		Submission of In Statement	tormation D	isciosure		
Fee Fee Fee Fee Description Code (\$)	581	40	581	40	Recording each (times number of	patent assig i properties)	nment per property		
103 18 203 9 Claims in excess of 20	146	740	246	370	Filing a submissi (37 CFR § 1 12	on after fina	al rejection		
102 84 202 42 Independent claims in excess of 3 104 280 204 140 Multiple dependent claim, if not paid	149	740	249	370	For each addition	nal inventior	n to be examined		
104 280 204 140 Multiple dependent claim, if not paid 109 84 209 42 ** Reissue independent claims	179	740	279	370	(37 CFR § 1.12 Request for Cont		nination (RCE)		
over original patent	169			900	Request for expe	edited exam	ination		
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	O+1	ner fee	' (specify		of a design appli	cation			
SUBTOTAL (2) \$0.00	-3 1		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,					
	┦ ",	duced	hv Basi	c Filma l	Fee Paid	SUBTO	TAL (3)		
**or number previously paid, if greater; For Reissues, see above	,,,,	Juceu	Jy Dasii	o i ming i		0	(
SUBMITTED BY		Regist	ration N	o.	27.003	Complete (f applicable) 919-483-	1012	
Name Virginia C. Bennett			ey/Agent)		37,092	Telephone			
Signature Bennett						Date	27 Feb. 0	<u> </u>	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF I	MAIL" (37 CFR 1.10)	Docket No. PK3065US3						
Serial No. To be assigned	Filing Date Concurrently herewith	Examiner	Group Art Unit					
Invention: PEPTIDES A	AND COMPOUNDS THAT BIND	TO A THROMBOPOIETIN RE	CEPTOR					
	e following correspondence: pplication under 37 C.F.R. 1.53(b							
(Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under								
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on (Date)								
		Ban Young (Typed or Printed Name of Person M						
Banyowan								
(Signature of Person Malling Correspondence) EV022025865US								
("Express Mail" Mailing Labet Number)								
	Note: Each paper must h	ave its own certificate of mailing.						

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DOWER et al.

Application No.: To be assigned Filing Date: Concurrently herewith

Title: PEPTIDES AND COMPOUNDS THAT BIND

TO A THROMBOPOIETIN RECEPTOR

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37, C.F.R. § 1.821-1.825

BOX PATENT APPLICATION Commissioner for Patents Washington, DC 20231

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- the submission, filed herewith in accordance with 37 C.F.R.§ 1.821 (g), does not include new matter;
- 2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R.§ 1.821 (c) and (e), respectively, are the same; and
- 3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted

February 27 , 2002

Date

Virginia C. Bennett

Attorney of Record, Reg. No. 37,092

GlaxoSmithKline Corporate Intellectual Property Department Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Phone: 919-483-1012

Facsimile: 919-483-7988